(Q44429695)

2 December 2017

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer (English)

1 reference

2 December 2017

6

Anna Jakubowska

1 reference

2 December 2017

8

Jan Lubinski

1 reference

2 December 2017

5

Steven A Narod

1 reference

2 December 2017

1

Michelle W Wong-Brown

1 reference

2 December 2017

2

Cliff J Meldrum

1 reference

2 December 2017

7

Helena Rudnicka

1 reference

2 December 2017

Jane E Carpenter

3

1 reference

2 December 2017

Christine L Clarke

series ordinal

4

1 reference

2 December 2017

Rodney J Scott

series ordinal

9

1 reference

2 December 2017

language of work or name

English

0 references

publication date

15 February 2015

1 reference

Breast Cancer Research and Treatment

2 December 2017

1 reference

2 December 2017

150

1 reference

2 December 2017

1

1 reference

2 December 2017

71-80

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-015-3293-7

2 December 2017

0 references

cites work

Breast cancer genetics: what we know and what we need

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

Familial Risks, Early-Onset Breast Cancer, and BRCA1 and BRCA2 Germline Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3293-7

10.1007/S10549-015-3293-7

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference